Glenmark Recalls Products in US for Manufacturing Issues

By By Rediff Money Desk, New Delhi
Oct 13, 2024 12:06
Glenmark Pharmaceuticals is recalling two products in the US, Ryaltris Nasal Spray and Ciclopirox Gel, due to manufacturing defects. The USFDA has classified the recalls as Class II and Class III.
New Delhi, Oct 13 (PTI) Drug firm Glenmark is recalling two products in the US due to manufacturing issues, according to the US Food and Drug Administration.

New Jersey-based Glenmark Pharmaceuticals Inc, USA, a unit of Mumbai-based Glenmark Pharmaceuticals, is recalling 45,504 bottles of Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray.

The company is recalling the affected lot due to "defective delivery system", the US Food and Drug Administration (USFDA) said in its latest enforcement report.

"The dip tube is clogged causing the spray not to work," it added.

Glenmark Pharmaceuticals Inc, USA, initiated the nationwide (US) Class II recall on September 24 this year.

As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

The US health regulator said the drug firm is also recalling a generic medication to treat certain fungal skin infections.

Glenmark Pharmaceuticals Inc, US, is recalling 11,568 tubes of Ciclopirox Gel, produced at the company's Goa-based plant, due to "defective container"," USFDA stated.

Firm received complaints of broken tubes at the seal, it added.

The company initiated the Class III recall on September 30.

As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".

India has the highest number of USFDA-compliant companies with plants outside the US.

The country is the largest supplier of generic medicines with around 20 per cent share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories.

The products manufactured in the country are shipped to over 200 countries around the globe, with Japan, Australia, West Europe, and the US as the main destinations.
Source: PTI
Read More On:
glenmarkdrug recallusfdaryaltrisciclopirox gel
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

Indian Markets This Week: Earnings, Inflation &...

Analysts predict market movements this week driven by corporate earnings, inflation...

Kinetic Engineering Invests Rs 30 Cr in EV...

Kinetic Engineering will invest Rs 30 crore in its subsidiary Kinetic Watts and Volts...

ATS Homekraft Sells 340 Luxury Flats on Dwarka...

ATS Homekraft has sold all 340 luxury apartments in its new 'Sanctuary 105' project on...

ShakthiSAT: Training 12k Girls in Space Tech...

Space Kidz India launches 'ShakthiSAT', a global mission to train 12,000 girls in space...

Indian Overseas Bank Opens Retail Loan...

Indian Overseas Bank launches new retail loan processing centers across India to...

Macrotech Developers Debt Rises to Rs 4,920 Cr

Macrotech Developers' net debt increased 14% to Rs 4,920 crore in Q2 FY25 due to...

SBI to Increase Instant Loan Limit for MSMEs

SBI plans to raise the threshold for its instant loan scheme for MSMEs, aiming to...

FLY91: Digital Native Airline Without Call Centre

FLY91, a regional airline, operates without a call centre, relying on automation and...

Gaurs Group to Invest Rs 4,000 Cr in Noida...

Gaurs Group, a leading real estate developer, will invest Rs 4,000 crore in a 17-acre...

Top 10 Indian Firms Mcap Erodes by Rs 1.22 Lakh...

Seven of India's top 10 most valued firms saw their market valuation decline by Rs 1.22...

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2024 Rediff.com